Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20⁺ lymphoid malignancies

Andrew W. Roberts, Ranjana H. Advani, Brad S. Kahl, Daniel Persky, John W. Sweetenham, Dennis A. Carney, Jianning Yang, Todd B. Busman, Sari H. Enschede, Roderick A. Humerickhouse, John F. Seymour

Research output: Contribution to journal › Article › peer-review